Breakthrough non-invasive liver tumor treatment now available at Ochsner MD Anderson

Breakthrough non-invasive liver tumor treatment now available at Ochsner MD Anderson

Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes primary liver tumors originating in the liver, or metastasized tumors resulting from another cancer spreading to the liver. Histotripsy is a new option for patients with liver tumors who may not be a candidate for surgery or other traditional therapies. 

Latest News From Ochsner Health


Ochsner Eat Fit is launching its 11th annual Alcohol Free For 40 Challenge on February 19, encouraging Louisianians to abstain from alcohol for 40 days to improve health and wellness. Participants will receive pre- and post-challenge metrics, including lab tests and body composition analysis, to measure the benefits of going alcohol-free. The initiative also includes support through a Facebook group, zero-proof cocktail recipes, and collaborations with local restaurants to promote healthier choices.


Read More

Five Ochsner Health hospitals have been named among Newsweek’s America’s Best-in-State Hospitals 2026, recognizing their clinical excellence, patient experience and innovation. This honor highlights Ochsner’s commitment to top-quality care across Louisiana, Mississippi and the Gulf South.


Read More

Ochsner Baton Rouge expands medical staff at OMC-The Grove, adding specialty expertise and patient access

Ochsner Baton Rouge welcomes several new physicians and advanced practice providers to Ochsner Medical Complex – The Grove.


Read More

Updates from To Your Health Blog